Braveheart Bio Statistics
Total Valuation
Braveheart Bio has a market cap or net worth of $1.51 billion. The enterprise value is $1.39 billion.
| Market Cap | 1.51B |
| Enterprise Value | 1.39B |
Important Dates
The last earnings date was Tuesday, September 8, 2026, after market close.
| Earnings Date | Sep 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Braveheart Bio has 64.17 million shares outstanding.
| Current Share Class | 64.17M |
| Shares Outstanding | 64.17M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +7.85% |
| Owned by Insiders (%) | 18.93% |
| Owned by Institutions (%) | 0.09% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 12.88 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.63, with a Debt / Equity ratio of 0.00.
| Current Ratio | 13.63 |
| Quick Ratio | 13.56 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -30.03% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.01M |
| Employee Count | 49 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 35.27 |
| Average Volume (20 Days) | 504,680 |
Short Selling Information
The latest short interest is 1.40 million, so 2.18% of the outstanding shares have been sold short.
| Short Interest | 1.40M |
| Short Previous Month | 847,773 |
| Short % of Shares Out | 2.18% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.89 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -35.40M |
| Pretax Income | -94.84M |
| Net Income | -98.46M |
| EBITDA | n/a |
| EBIT | -35.40M |
| Earnings Per Share (EPS) | -$14.68 |
Balance Sheet
The company has $122.83 million in cash and $575,000 in debt, with a net cash position of $122.26 million or $1.91 per share.
| Cash & Cash Equivalents | 122.83M |
| Total Debt | 575,000 |
| Net Cash | 122.26M |
| Net Cash Per Share | $1.91 |
| Equity (Book Value) | 117.61M |
| Book Value Per Share | -11.48 |
| Working Capital | 114.39M |
Cash Flow
In the last 12 months, operating cash flow was -$24.15 million and capital expenditures -$28,000, giving a free cash flow of -$24.18 million.
| Operating Cash Flow | -24.15M |
| Capital Expenditures | -28,000 |
| Depreciation & Amortization | 5,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -24.18M |
| FCF Per Share | -$0.38 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Braveheart Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -6.50% |
| FCF Yield | -1.60% |
Analyst Forecast
The average price target for Braveheart Bio is $45.25, which is 91.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $45.25 |
| Price Target Difference | 91.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |